First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study - Balar, AV; Castellano, D; O'Donnell, PH (Lancet Oncol, 2017)
et al.